Ilios Therapeutics, founded with a mission to combat neurodegenerative diseases, focuses on pioneering pre-clinical solutions for conditions like Alzheimer's. The company leverages an innovative chemistry platform to develop first-in-class small molecules that modulate protein misfolding, oxidative stress, and neuro-inflammation. By combining decades of research with an entrepreneurial spirit, Ilios aims to deliver multi-functional therapeutics that address the complex mechanisms underlying neurodegeneration.

Notable figures affiliated with Ilios Therapeutics include leading researchers and industry experts in neurodegenerative disease. The company has attracted significant interest from investors committed to advancing medical breakthroughs in this field. Key achievements include the development of their "Trojan Horse" strategy, which effectively delivers multi-functional drugs to the brain. Ilios's impact is marked by its potential to transform the treatment landscape for devastating neurodegenerative conditions, offering hope for millions affected worldwide.